Penicillin G sodium prices in the United States moved sharply higher in March as tight import availability supported firmer spot offers. Early-month shipments from China and India were limited, while mid-month regulatory scrutiny and contamination incidents reduced exportable volumes. Hospitals and injectable manufacturers accelerated call-offs, with distributors reporting higher releases; livestock producers front-loaded purchases ahead of spring vaccination windows. Late-month activity left Houston free-trade-zone stocks near minimum cover and pressured buyers to accept firmer quotes, creating a bullish backdrop for CFR Houston spot supply into April. Demand across markets was uneven but supportive of higher pricing: healthcare strengthened as hospitals and injectables increased spot tenders and substituted Penicillin G for out-of-stock cefuroxime injectables; retail pharmacy demand remained weak as oral derivatives dominate. Livestock and veterinary demand was moderate due to spring metaphylaxis programs. Upstream costs rose, lifting variable fermentation expenses. ChemAnalyst projects continued firmness into spring.
